化合物 azd1390|T5175|TargetMol

价格	￥678	￥980	￥1450
包装	1mg	2mg	5mg

最小起订量	1mg
发货地	上海
更新日期	2025-02-28

QQ交谈微信洽谈

产品详情

中文名称:化合物 azd1390	英文名称:azd1390
CAS:2089288-03-7	品牌: TargetMol
产地: 美国	保存条件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
纯度规格: 99.38%	产品类别: 抑制剂
货号: T5175

Product Introduction

Bioactivity

名称	azd1390
描述	AZD1390 is an exceptionally potent inhibitor of ATM in cells (IC50: 0.78 nM) with >10,000-fold selectivity over closely related members of the PIKK family of enzymes.
细胞实验	Cells were seeded in six-well plates to a density of 50 to 60% and incubated at 37°C for 24 hours. Cells were pretreated with AZD1390, the ATR inhibitor AZD6738, the Wee1 inhibitor AZD1775, the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib, or the DNA-PK inhibitor KU-0060648 at indicated concentrations for 1 hour and subsequently irradiated at 2 Gy using the Faxitron CellRad (130-kV, 5-mA, 0.5-mm Al). In washout experiments, the cell culture medium was immediately replaced and cells were incubated with or without the compound for 1, 6, and 24 hours. In all other experiments, proteins were collected at indicated time points following irradiation. Proteins were harvested by scraping the cells in radioimmunoprecipitation assay (RIPA) lysis buffer supplemented with protease and phosphatase inhibitors. Protein content was quantified using the BCA Protein Assay Kit according to manufacturing conditions. Proteins were separated by SDS–polyacrylamide gel electrophoresis on 4 to 12% bis-tris or 3 to 8% Tris-acetate gels and transferred onto nitrocellulose membranes using the iBlot Dry Blotting System. Membranes were briefly washed with water and Tris-buffered saline (TBS) with 0.05% Tween 20 (TBST) once and incubated in blocking solution, followed by primary antibodies diluted in TBST with 5% (w/v) nonfat dry milk or 3% bovine serum albumin (BSA) overnight at 4°C with shaking. Membranes were then washed three times and incubated for 1.5 hours with horseradish peroxidase (HRP)–conjugated antibodies and/or LI-COR fluorescent antibodies CW700-800 in TBST with 5% (w/v) nonfat dry milk. Membranes were washed five times with TBST, and proteins were visualized with the Fuji or Syngene G:BOX Imaging System or Film Developer after enhanced chemiluminescence substrate addition.
动物实验	Bioluminescence signaling of implanted 3 × 10^5 NCI-H2228-Luc cells was measured using an IVIS Xenogen imaging machine to monitor tumor growth. When the signal reached the range of 10^7 to 10^8, the mice were randomized into different treatment groups and treated orally with either vehicle or AZD1390 QD or BID + IR at 2.5 Gy daily for four consecutive days. AZD1390 or vehicle was dosed at 1 hour before IR on each dosing day. The bioluminescence signals and body weight of the mice were measured once weekly, and the raw data were recorded according to their study number and measurement date in the in vivo database. TGI from the start of treatment was assessed by comparison of the mean change in bioluminescence intensity for the control and treated groups and presented as % of TGI. The calculation of inhibition and regression was based on the geometric mean of relative tumor volume (RTV) in each group. "CG" means the geometric mean of RTV of the control group, whereas "TG" means the geometric mean of RTV of the treated group. On specific day, for each treated group, the inhibition value was calculated using the following formula: Inhibition% = (CG ? TG) * 100/(CG ? 1). CG should use the corresponding control group of the treated group during calculation. If inhibition was >100%, then regression was calculated using the following formula: Regression = 1 – TG. Statistical significance was evaluated using a one-tailed t-test. Survival benefit was measured by Kaplan-Meier plots at the end of the study.
体外活性	AZD1390对ATM自磷酸化的抑制在治疗后4小时发生，3 nM在LN18 GBM细胞中产生了强烈的ATM抑制效果。在相同条件下测试的其他DDR抑制剂，即便是在相关IC50浓度下，也未对pATM水平产生影响。在使用AZD1390及2 Gy辐射处理24小时后，观察到G2阶段累积量呈剂量依赖性增加，这表明细胞没有在S期停滞，而是在G2阶段累积或在有丝分裂过程中遇到问题。
体内活性	在体内同源和患者来源的胶质瘤模型以及原位肺脑转移模型中，AZD1390与每日分割的IR（全脑或立体定向放射治疗）联合使用，显著促进了肿瘤退缩并提高了动物存活率。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 4.77 mg/mL (9.98 mM), Sonication is recommended.
关键字	azd1390 \| ATM/ATR \| azd-1390 \| ATM and RAD3 related \| AZD 1390 \| inhibit \| Inhibitor \| Ataxia telangiectasia mutated
相关产品	Schisandrin B \| Ceralasertib \| AZ31 \| Berzosertib \| KU60019 \| Elimusertib \| CP-466722 \| GJ103 sodium salt \| Ro 90-7501 \| NU6027 \| (Z)-Mirin \| Dactolisib
相关库	抑制剂库 \| 经典已知活性库 \| 抗癌活性化合物库 \| 已知活性化合物库 \| 激酶抑制剂库 \| 高选择性抑制剂库 \| 酪氨酸激酶分子库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

关键字： azd1390|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	2013-04-18 （13年）	注册资本	566.265100万人民币
员工人数	100-500人	年营业额	￥ 1亿以上
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务	经营模式	贸易,工厂,试剂,定制,服务

TargetMol中国（陶术生物）

VIP 3年

公司成立：13年
注册资本：566.265100万人民币
企业类型：有限责任公司(自然人投资或控股)
主营产品：小分子抑制剂、药物筛选化合物库、药物筛选等
公司地址：静安区江场三路238号8楼

进入店铺

询盘

店内推荐

化合物 Tetrahydrocurcumin D6|T13135|TargetMol

￥3200

化合物 BMS3|T4600|TargetMol

￥179

左旋奥硝唑|T12324|TargetMol

￥153

化合物 azd1390|T5175|TargetMol相关厂家报价

产品名称	价格		公司名称	报价日期
aladdin 阿拉丁 A408361 AZD1390 2089288-03-7 10mM in DMSO	￥2621.90	VIP2年	上海阿拉丁生化科技股份有限公司	2025-02-27
7-氟-1-异丙基-3-甲基-8-(6-(3-(哌啶-1-基)丙氧基)吡啶-3-基)-1H-咪唑并[4,5-C]喹啉-2(3H)-酮	询价	VIP3年	陕西西化化学工业有限公司	2025-02-19
7-氟-1-异丙基-3-甲基-8-(6-(3-(哌啶-1-基)丙氧基)吡啶-3-基)-1H-咪唑并[4,5-C]喹啉-2(3H)-酮 2089288-03-7	询价	VIP3年	陕西西化化学工业有限公司	2025-02-19

内容声明:
以上所展示的信息由商家自行提供，内容的真实性、准确性和合法性由发布商家负责。商家发布价格指该商品的参考价格，并非原价，该价格可能随着市场变化，或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格，请咨询商家，以实际成交价格为准。请意识到互联网交易中的风险是客观存在的